Abstract
A novel series of 3a, 6a – Dihydro-1H- pyrrolo[ 3,4-c] pyrazole-4,6-dione Derivatives have been reported as better anti-HIV 1 agents. In this study QSAR was carried on a 3a, 6a – Dihydro-1H- pyrrolo[ 3,4-c] pyrazole-4,6-dione Derivatives as anti HIV – 1 agents. Two different variable selection approaches namely: Genetic function approximation and multi linear regression models were used to predict the HIV-1 inhibition activity. The following were obtained after the model was internally validated: squared correlation coefficient (R2) of 0.8823, adjusted squared correlation coefficient (R2adj) of 0.8528 and leave one out (LOO) cross validation coefficient (Q2cv) of 0.7566. The external validation was carried out to confirm the predictive power of the model and R2pred of 0.6901 was obtained. The validated model result above showed that the five descriptors which are GATS6c, VR3_Dze, minHCsats, RDF30m and Eze contributed positively to the activity. The result obtained will be very helpful for designing and synthesizing other derivatives with improved anti-HIV activities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
